. Author manuscript; available in PMC: 2011 Dec 6.

Published in final edited form as: Pediatrics. 2010 Sep 20;126(4):e884–e894. doi: 10.1542/peds.2009-3535

Table 3. Iron Status of Infants With and Without IDA During the Course of Iron Therapy.

	6-mo Cohort		12-mo Cohort

	IDA	Nonanemic	IDA	Nonanemic
Hemoglobin, g/L
Pretreatment^a	95.0 ± 0.8	121.4 ± 0.6	104.1 ± 0.6	125.4 ± 0.6
After 6 mo of iron^a,^b	118.0 ± 1.2	127.1 ± 0.9	120.4 ± 0.9	129.2 ± 1.1
After 12 mo of iron	122.1 ± 1.5	126.5 ± 1.8	124.4 ± 1.2^a,^b	130.5 ± 1.4^a,^b
Mean corpuscular volume, fL
Pretreatment^a	66.1 ± 0.6	73.8 ± 0.4	66.9 ± 0.5	76.4 ± 0.4
After 6 mo of iron^a,^b	72.7 ± 0.5	76.6 ± 0.4	73.7 ± 0.5	78.2 ± 0.5
Free erythrocyte protoporphyrin, μg/dL RBC
Pretreatment^a	185.7 ± 12.3	95.0 ± 3.1	163.4 ± 6.9	80.5 ± 1.7
After 6 mo of iron^a,^b	97.5 ± 3.5	76.6 ± 2.3	92.7 ± 4.1	69.1 ± 2.3
Ferritin, μg/L
Pretreatment^a	10.9 ± 1.3	17.8 ± 1.9	6.2 ± 0.8	14.5 ± 1.1
After 6 mo of iron^a,^b	18.8 ± 1.8	25.0 ± 2.3	15.7 ± 1.3	23.7 ± 2.1

Values are mean ± SE. RBC indicates red blood cells.

Difference between IDA and nonanemic groups

change within group from previous time point significant at P< .05 for both cohorts. The only exception was hemoglobin after 12 months of iron, for which the difference between IDA and nonanemic groups and the within-group increase from 6 to 12 months of iron treatment were not significant in the 6-month cohort.